Navigation Links
Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
Date:4/16/2008

BEIJING, April 16 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a pharmaceutical company in the People's Republic of China ("PRC"), today announced that it will conduct a conference call at 9:00 a.m. Eastern Time on Thursday, April 17, 2008 to discuss the fourth quarter and fiscal year 2007 results.

Joining Mr. Zhongyi Liu, Chief Executive Officer and President of Lotus Pharmaceuticals, Inc., will be Mr. Adam Wasserman, Chief Financial Officer. The Company plans to issue an earnings announcement prior to the call.

To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 800-688-0796. International callers should dial 617-614-4070. The Conference Passcode for this call is 615 756 86.

If you are unable to participate in the call at this time, a replay will be available for fourteen days starting on Thursday, April 17, 2008 at 11:00 a.m. Eastern Time. To access the replay, dial 888-286-8010, international callers dial 617-801-6888, Conference Passcode 35016441.

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. ("Lotus") controls and operates Liangfang Pharmaceutical, Ltd. ("Liangfang") and Enze Jiashi Pharmaceutical, Ltd. ("Enze"), two Chinese pharmaceutical companies located in Beijing. Liangfang and Enze form a large comprehensive enterprise, which deals in an integration of the production, trade, sales and marketing of pharmaceuticals. Together, they possess some of the most advanced pharmaceutical-production equipment used in China, workshops authenticated by the National GMP, a suite of various medicines produced by Liangfang and/or Enze (together, "Lotus East"), and a number of high-tech personnel. Lotus East has business and office facilities of 2,000 square meters, warehouse of 1,000 square meters and operates ten retail pharmacies in the Beijing area. Lotus East performs scientific research on new medicines, and the production, wholesale and retail sale of medicines. For more information, visit http://www.LotusEast.com .

Safe Harbor Statement

Certain statements set forth in this press release constitute "forward-looking statements". Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

For more information, please contact:

Lotus Pharmaceuticals, Inc.

Mr. Adam Wasserman, CFO

Tel: +86-877-801-0344

Email: info@LotusEast.com

CCG Elite Investor Relations Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lotus Pharmaceuticals Raises $5 Million in Private Placement
2. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
3. Lotus Blossom Consulting Announces E-Book on Infertility Treatment Financing
4. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
5. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
6. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
7. Barr Pharmaceuticals, Inc. Executive Bios
8. Alseres Pharmaceuticals, Inc. Raises $5 Million
9. Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
10. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
11. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Maryland (PRWEB) , ... May 24, 2016 , ... ... announced the appointment of Jonathan (Jon) Otterstatter to its board of ... is a proven leader in the development of technological innovations that lead to ...
(Date:5/24/2016)... ... May 24, 2016 , ... WaterAid launched the #perioddrama campaign to mark Menstrual Hygiene ... billion women around the world who do not have access to a toilet, even when ... about their dread of #perioddrama. The (sometimes hilarious) results help shine a light on the ...
(Date:5/24/2016)... ... May 24, 2016 , ... Aloria Health Announces ... Begin In June , Aloria Health, specializing in a re-imagined, client-oriented approach to ... Milwaukee, its first treatment facility for outpatient, day treatment and residential care. Aloria ...
(Date:5/24/2016)... ... May 24, 2016 , ... Global ... and education, today announced that it has named Scott Santarella as its new ... Addario Lung Cancer Foundation (ALCF) in San Francisco, where he successfully helped to ...
(Date:5/24/2016)... , ... May 24, 2016 , ... Dignity Health has ... month. The new facility is licensed under Dignity Health Arizona General Hospital, which ... of Dignity Health in Arizona, said that the new facility will complement Dignity Health’s ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 24, 2016 Los innovadores ... del mundo, introduce catéteres para la intervención de ... una compañía global especializada en el suministro de ... su cartera incluyendo productos para tratar la enfermedad ... PTA son los dispositivos de primera entrada de ...
(Date:5/24/2016)... -- Een app die artsen over de ... kunnen behandelen, hun kennis kunnen delen en van elkaar ... en revolutionaire MDLinking App, ontwikkeld door een internationale groep ... Flu en oncologisch chirurg dr. Gijs van Acker ... op dinsdag 24 mei officieel gepresenteerd op het Amsterdam ...
(Date:5/23/2016)... May 23, 2016 Transparency Market ... Exocrine Pancreatic Insufficiency Market - Global Industry Analysis, Size, ... According to the report, the exocrine pancreatic insufficiency market ... from 2015 to 2023 to reach US$2.85 Bn by ... condition characterized by the deficiency of the exocrine pancreatic ...
Breaking Medicine Technology: